Annual report [Section 13 and 15(d), not S-K Item 405]

Schedule of Reconciliation of Adjusted EBITDA (Details)

v3.26.1
Schedule of Reconciliation of Adjusted EBITDA (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Segment Reporting Information [Line Items]    
Income from continuing operations (GAAP Basis) $ (4,100)  
Stock-based compensation 35 $ 291
Severance & related expense 700  
Asset impairment - lab supplies 198
Tax (benefit) expense (21,210) 4
Interest accretion expense 34
Change in fair value of note payable 110 547
Reportable Segment [Member]    
Segment Reporting Information [Line Items]    
Income from continuing operations (GAAP Basis) 24,984 6,946
Depreciation and amortization 425 300
Stock-based compensation 35 291
Severance & related expense 692
Asset impairment - lab supplies 198
Tax (benefit) expense (21,210) 4
Interest accretion expense 34
Note payable interest 168 625
Other expense/income, net 32 (48)
Change in fair value of note payable 110 547
Adjusted EBITDA $ 5,434 $ 8,699